Vol 71, No 1 (2020)
Original paper
Published online: 2019-11-26

open access

Page views 3307
Article views/downloads 1036
Get Citation

Connect on Social Media

Connect on Social Media

Screening of potential biomarkers in the occurrence and development of type 1 diabetes mellitus based on transcriptome analysis

Jianhua Kang1, Xingya Shen1, Lishun Yang1, Shaohua Feng1, Deilai Li1, Haisheng Yuan1
Pubmed: 33140399
Endokrynol Pol 2020;71(1):58-65.


Introduction: The aim of the study was to reveal the mechanisms for the pathogenesis and progression of type 1 diabetes mellitus (T1DM).

Material and methods: Two mRNA expression profiles and two miRNA expression profiles were downloaded from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs), differentially expressed miRNAs (DEMs), functional enrichment analyses, pathways, putative targets for DEMs and the miRNA-gene pairs, protein-protein pairs of DEGs, and PPI network were constructed.

Results: Based on mRNA expression profiles, 37 and 110 DEGs were identified, and named as DEGs-short and DEGs-long, respectively. Based on miRNA expression profiles, 15 and six DEMs were identified, and named as DEMs-short and DEMs-long, respectively. DEGs-short were enriched in six GO terms and four pathways, and DEGs-long enriched in 40 GO terms and 10 pathways. Seventeen miRNA-gene pairs for DEMs-short were screened out; hisa-miR-181a and hisa-miR-181c were involved in the most pairs. Twenty pairs for DEMs-long were obtained; hsa-miR-338-3p was involved in all the pairs. KLRD1 was involved in more pairs in the network of DEGs-short. ACTA2 and USP9Y were involved in more pairs in the network of DEGs-long.

Conclusions: KLRD1, hisa-miR-181a, and hisa-miR-181c might be pathogenic biomarkers for T1DM, ACTA2, USP9Y, and hsa-miR-338-3p progressive biomarkers of T1DM. 

Article available in PDF format

View PDF Download PDF file


  1. Iwahashi H, Imagawa A. Type 2 diabetes mellitus prevention strategy: Target and goal in Japanese men. J Diabetes Investig. 2016; 7(3): 283–285.
  2. Treating the Inflammatory Core of Metabolic Syndromes. EBioMedicine. 2015; 2(9): 1003–1004.
  3. Daneman D. Type 1 diabetes. The Lancet. 2006; 367(9513): 847–858.
  4. Knip M, Veijola R, Virtanen SM, et al. Environmental triggers and determinants of type 1 diabetes. Diabetes. 2005; 54 Suppl 2: S125–S136.
  5. Li Yy, Gong Ge, Geng Hy, et al. CTLA-4 +49A/G gene polymorphism and type 1 diabetes mellitus in the Chinese population: a meta-analysis of 2238 subjects. International Journal of Diabetes in Developing Countries. 2015; 36(1): 45–51.
  6. Arroyo-Jousse V, Garcia-Diaz DF, Codner E, et al. Epigenetics in type 1 diabetes: TNFa gene promoter methylation status in Chilean patients with type 1 diabetes mellitus. Br J Nutr. 2016; 116(11): 1861–1868.
  7. Fang C, Huang Y, Pei Y, et al. Genome-wide gene expression profiling reveals that CD274 is up-regulated new-onset type 1 diabetes mellitus. Acta Diabetol. 2017; 54(8): 757–767.
  8. Assmann TS, Recamonde-Mendoza M, De Souza BM, et al. MicroRNA expression profiles and type 1 diabetes mellitus: systematic review and bioinformatic analysis. Endocr Connect. 2017; 6(8): 773–790.
  9. Kaidonis G, Gillies MC, Abhary S, et al. A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients. Acta Diabetol. 2016; 53(4): 643–650.
  10. Ambros V. The functions of animal microRNAs. Nature. 2004; 431(7006): 350–355.
  11. Lowe R, Shirley N, Bleackley M, et al. Transcriptomics technologie. PLoS Comput Biol. 2017; 13(5): e1005457.
  12. Yang M, Ye L, Wang B, et al. Decreased miR-146 expression in peripheral blood mononuclear cells is correlated with ongoing islet autoimmunity in type 1 diabetes patients 1miR-146. J Diabetes. 2015; 7(2): 158–165.
  13. Garcia-Contreras M, Shah SH, Tamayo A, et al. Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes. Sci Rep. 2017; 7(1): 5998.
  14. Collares, C, Evangelista A, Xavier D. Meta-analysis of differentially expressed microRNAs in type 1, type 2 and gestational diabetes mellitus. Endocrine Abstracts. 2012; 29(OC17.6).
  15. Saudek F, Havrdova T, Boucek P, et al. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud. 2004; 1(2): 80–88.
  16. Zitman-Gal T, Green J, Pasmanik-Chor M, et al. Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment. Cardiovasc Diabetol. 2014; 13: 8.
  17. Yang G, Wu Y, Ye S. MiR-181c restrains nitration stress of endothelial cells in diabetic db/db mice through inhibiting the expression of FoxO1. Biochem Biophys Res Commun. 2017; 486(1): 29–35.
  18. Nakata S, Imagawa A, Miyata Y, et al. Low gene expression levels of activating receptors of natural killer cells (NKG2E and CD94) in patients with fulminant type 1 diabetes. Immunol Lett. 2013; 156(1-2): 149–155.
  19. Goodier MR, Nawroly N, Beyan H, et al. Identical twins discordant for type 1 diabetes show a different pattern of in vitro CD56+ cell activation. Diabetes Metab Res Rev. 2006; 22(5): 367–375.
  20. Jacovetti C, Abderrahmani A, Parnaud G, et al. MicroRNAs contribute to compensatory β cell expansion during pregnancy and obesity. J Clin Invest. 2012; 122(10): 3541–3551.
  21. Nesca V, Guay C, Jacovetti C, et al. Identification of particular groups of microRNAs that positively or negatively impact on beta cell function in obese models of type 2 diabetes. Diabetologia. 2013; 56(10): 2203–2212.
  22. Nagamoto T, Eguchi G, Beebe DC. Alpha-smooth muscle actin expression in cultured lens epithelial cells. Invest Ophthalmol Vis Sci. 2000; 41(5): 1122–1129.
  23. Wu Z, Wang S, Jiang F, et al. Mass spectrometric detection combined with bioinformatic analysis identified possible protein markers and key pathways associated with bladder cancer. Gene. 2017; 626: 407–413.
  24. Zhu Y, Ren S, Jing T, et al. Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome. Urol Oncol. 2015; 33(9): 384.e9–384.20.
  25. Russo P, Siani A, Miller MA, et al. Genetic variants of Y chromosome are associated with a protective lipid profile in black men. Arterioscler Thromb Vasc Biol. 2008; 28(8): 1569–1574.